Nav: Home

Putting a brake on leukemia cells

June 09, 2016

Biomarkers play an important role in modern cancer medicine. They are used as tools to diagnose cancers more precisely and to better predict the course of the disease. One marker that is frequently associated with leukemia is a chromosomal abnormality called t(8;21) translocation, in which a part of chromosome 8 connects with chromosome 21. Back in the 1970s, researchers already recognized that in a substantial percentage of patients suffering from acute myeloid leukemia (AML), the transformed cells exhibited this chromosomal abnormality. However, scientific studies also showed that the chromosomal rearrangement alone is not sufficient to cause leukemia. In a research project as part of the German Cancer Consortium (DKTK), researchers at the Department of Internal Medicine 3, Munich University Hospital (LMU), have now discovered a new mutation that promotes the growth of cancer cells. The mutation in the ZBTB7A gene boosts the energy metabolism in the cells. "In healthy cells, the active ZBTB7A gene acts like a parking brake on metabolism," said Philipp Greif, who leads the DKTK Junior Research Group "Pathogenesis of Acute Myeloid Leukemia" at LMU. "If the gene is defective, cancer cells get more energy to use for proliferation." Reversely, the scientists were able to show that the growth rate of leukemia cells can be reduced by genetically modifying the cancer cells in such a way that they produce higher levels of active ZBTB7A. The investigators also observed an indication of the gene's growth-inhibiting effect in the clinic: Leukemia patients in whose cancer cells the gene was transcribed at higher levels had significantly better chances of survival than patients in whom the gene was hardly active or not active at all.

Philipp Greif is one of the clinical researchers at the DKTK who are trying to find new, more targeted approaches in the treatment of cancer patients. "Assessing the course of the disease using genetic markers helps us recommend the right therapy," Greif said. "In some cases, the leukemia may be curable with chemotherapy alone, while in others, subsequent stem cell transplantation is the only chance for the patients to be cured." Using the available sample material at the LMU Laboratory for Leukemia Diagnostics and the collections at the other DKTK sites, the scientists now plan to explore whether the new marker can be used to customize therapies for individual patients.

The discovery is also a promising starting point for developing new approaches toward treating AML patients. "It might be possible to use specially modified glucose molecules to block the energy production process in AML cells," said Luise Hartmann, who is the first author of the study. "Initial clinical trials in other cancers have already shown that these agents are well tolerated by patients" About a quarter of all leukemia patients with the t(8;21) chromosomal abnormality display the mutated ZBTB7A gene. But the scientists also observed a clear link between the gene's activity and the course of the disease in leukemia patients in whose cancer cells no mutations in the ZBTB7A gene were detected. "Therapy with the metabolic inhibitor might therefore work in a wider circle of patients," Greif said. This approach might also become interesting for other types of cancer. ZBTB7A mutations also occur in other cancers, such as in gut cancer.
-end-
Hartmann, L. et. al.: ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation. In: Nature Communications (June 2, 2016) D

Funding: This project was supported by the Wilhelm Sander Foundation (2014.162.1) and SFB 1243 "Cancer Evolution" of the German Research Foundation (DFG).

In the German Cancer Consortium (DKTK), the German Cancer Research Center (DKFZ) joins up with universities and university hospitals all over Germany specially designated to clinical oriented cancer research. As DKTK's core center the DKFZ works together with research institutions and hospitals in Berlin, Dresden, Essen/Düsseldorf, Frankfurt/Mainz, Freiburg, Munich, Heidelberg and Tübingen to create the best possible conditions for clinical cancer research. The consortium promotes interdisciplinary research at the interface between basic research and clinical research, as well as clinical trials for innovative treatments and diagnostic methods. Another key focus of the consortium's work is on developing research platforms to speed up the application of personalized cancer treatments and to improve the diagnosis and prevention of cancer. The German Cancer Consortium (DKTK) is a joint long-term initiative involving the German Federal Ministry of Education and Research (BMBF), participating German states and the German Cancer Research Center (DKFZ) and was established as one of six German Health Research Centres (DZGs).

German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)

Related Cancer Articles:

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...